Publications by authors named "H McFall"
The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants has significantly reduced the efficacy of some approved vaccines. A fourth dose of NVX-CoV2373 (5 µg SARS-CoV-2 recombinant spike [rS] protein + 50 µg Matrix-M™ adjuvant; Novavax, Gaithersburg, MD) was evaluated to determine induction of cross-reactive antibodies to variants of concern. A phase II randomized study (NCT04368988) recruited participants in Australia and the United States to assess a primary series of NVX-CoV2373 followed by two booster doses (third and fourth doses at 6-month intervals) in adults 18-84 years of age.
View Article and Find Full Text PDFArticle Synopsis
- The study investigates the safety and immune response of a booster dose of a SARS-CoV-2 vaccine (NVX-CoV2373) to combat waning vaccine efficacy and emerging variants.
- A phase 2 randomized trial involved healthy adults aged 18-84 years, with criteria focusing on BMI and excluding individuals with certain health conditions or who were pregnant.
- Participants were assigned to receive either a placebo or the NVX-CoV2373 booster after six months post their initial two-dose vaccination, and the primary endpoints included safety and reactogenicity of the vaccine.
Vaccines are considered the most economical and effective preventive measure against most deadly infectious diseases. Vaccines help protect around three million lives every year, but hundreds of thousands of lives are lost due to the instability of vaccines. This review discusses the various types of instability observed, while manufacturing, storing, and distributing vaccines.
View Article and Find Full Text PDFArticle Synopsis
- The study aimed to improve the solubility and bioavailability of aripiprazole (ARI) by creating pH-modulated solid dispersions through hot-melt extrusion (HME) technology.
- Various materials were tested, with Kollidon® 12 PF and succinic acid being chosen for their effectiveness, and the resulting formulations were analyzed for changes in drug structure and performance.
- The selected formulation, N6, showed significantly enhanced solubility and oral bioavailability compared to pure ARI, indicating the potential of these techniques for better drug release.